Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.
Developer of an optical testing product intended for postoperative monitoring and treatment. The company's product makes the postoperative management of dislocated intraocular lenses intuitive and straightforward, enabling patients to reduce post-operative refractive issues after cataract surgery.
CYTO365 is the manufacturer of RondelO multi inlet stopcock, which is sold as a component aimed to be integrated into IV-set to combat Drug Incompatibility due to parallel infusion.
Selio is a simple, effective and patent protected technology. The Selio prototype has been rigorously tested in the lab and in subsequent acute pre-clinical in vivo studies with very positive results.
AMT Medical BV has developed a minimal invasive medical device for heart bypass surgery. The AMT Heart Bypass System is based on the ELANA bypass, technology invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team of the UMCU. The technique is designed to make the traditional heart bypass procedures faster, safer, easier and less invasive for the patient.The product has been fully developed, production process has been designed, all pre-clinical trials have finished, a clinical multi-center trial will commence late 2019, early 2020.
Ganymed Robotics SAS, a medical device company, focuses on the development of robotics technologies for orthopedic surgeons. It develops a therapeutic device to enhance surgical precision in knee replacement surgery. The company was incorporated in 2018 and is based in Paris, France.
Restore Medical develops and provides a device-based therapy for congestive heart failure. It improves patient quality of life and reduce hospital readmission rates. Restore Medical's product, ContraBand, is a novel catheter-delivered implant in the pulmonary arteries for treatment of left ventricle failure, for patients with preserved right ventricle function. Restore Medical was founded in 2016 and is headquartered in Or Yehuda, Israel.
IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
Methinks Software, founded in 2016 and based in Barcelona, Spain, specializes in developing artificial intelligence medical software focused on stroke diagnosis and treatment. Utilizing advanced techniques from Google's deep learning framework, TensorFlow, the company analyzes neuroimaging to provide timely and accurate diagnoses of brain-related diseases, particularly acute strokes. Its medical imaging platform enables rapid assessment from non-contrast CT scans, streamlining the diagnosis process and facilitating improved communication between radiologists, hospitals, stroke units, and healthcare professionals. By bypassing the need for contrast CT scans, Methinks aims to reduce time-to-treatment, ultimately enhancing clinical outcomes and patient care in emergency settings.
Orixha has developped an innovative device for cooling patients within few minutes and thus improve their prognosis by using a dedicated liquid ventilator able to perform safe and efficient total liquid ventilation. This method consists in filling the lungs with liquid perfluorocarbons and due to the high gases solubility and the large pulmonary sufaces can use the lungs as heat exchanger.
GlucoSet AS is a medical device company based in Trondheim, Norway, specializing in the design and manufacturing of sensor-based blood glucose monitoring tools for use in Intensive Care Units (ICUs). Founded in 2011, GlucoSet focuses on developing intravascular sensor technology that provides continuous and accurate monitoring of blood glucose levels in critically ill patients. This technology addresses the challenges of elevated and unstable glucose levels in ICU settings, which can lead to costly complications, prolonged hospital stays, and increased mortality rates. By delivering real-time glucose information, GlucoSet's system enables healthcare professionals to effectively manage glucose levels, thereby minimizing the risk of harmful hypoglycemia and improving overall patient outcomes.
Synergia Medical SA, founded in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in the development of innovative neurostimulation medical devices. The company is focused on creating optoelectronic neurostimulators that utilize advanced materials, optical components, biosensors, and microelectronics. In particular, Synergia Medical aims to manufacture MRI-safe, implanted devices designed for treating drug-resistant epilepsy, with potential applications in other therapeutic areas. The company has achieved ISO13485 certification within a short period and has successfully developed and marketed an OEM external neurostimulator for motorized amputee prostheses. Supported by private investors and public research grants, Synergia Medical has rapidly expanded its team to include thirteen skilled professionals dedicated to advancing neurostimulation technology.
ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of an anatomically shaped polymer-based meniscus implant known as the Trammpolin. This innovative implant is designed to restore the protective function of the meniscus by acting as a spacer in the joint. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise gained from a collaborative initiative that began in 2010, which included universities, private companies, and support from the Dutch government. The company combines clinical, biomechanical, and polymer knowledge to advance the Trammpolin design and its prototype development.
KOVE is a medical device company.
Artiria Medical SA develops micro-actuated device to treat vascular diseases. Its products bring micromotion deep in the brain arteries, enabling a navigation and stroke treatment. It empowers catheters and guidewires. Artiria Medical SA was incorporated in 2019 and is based in Lausanne, Switzerland.
Piomic is a developer of a portable, hand-held medical device designed to treat chronic wounds, specifically targeting chronic leg and foot ulcers. The device utilizes optical and magnetic stimulation technologies to promote wound healing, aiming to alleviate the significant burden posed by the estimated 50 million patients suffering from hard-to-heal wounds globally. Clinical studies have demonstrated that the treatment is safe, accelerates wound closure, reduces pain, and enhances the overall quality of life for patients. The device features a simple, single-button operation, allowing for seamless integration into various healthcare settings, including stationary facilities, ambulatory care, and home use. Through its innovative approach, Piomic seeks to improve patient outcomes and provide a more effective solution for managing chronic wounds.
Legacy Healthcare is a biopharma company focused on the development of oncology supportive care and dermatology drugs
Nuclidium’s vision is to address the unmet need to detect and stage cancer more accurately so that treatment options for cancer patients and their long-term survival can be significantly improved.
OxyPrem AG is a Swiss company that develops, designs, and manufactures advanced sensor solutions specifically for monitoring preterm infants. Founded in 2018 and based in Zurich, it offers a reusable oxygen sensor that continuously measures hemoglobin oxygen saturation in any human tissue, particularly focusing on the brains of high-risk preterm infants. By employing noninvasive near-infrared light technology, the device provides real-time monitoring, enabling healthcare professionals to prevent severe outcomes such as early death or long-term brain damage in this vulnerable population. OxyPrem's innovative approach not only enhances clinical care but also significantly reduces medical waste associated with single-use devices.
PrediSurge is a software company that offers design and support solutions for physicians and medical device companies.
AdjuCor is a high-tech medical device company that owns and is responsible for development, production, marketing and selling of a revolutionary technology for the treatment of end-stage heart failure patients. Its flagship product is called BEAT. The market introduction of BEAT will be the world’s first commercially available, minimal invasive application of mechanical circulatory support for the failing heart. It provides uni- or biventricular support, while also completely avoiding contact with blood. This unique feature set will allow for the transformation of standard-of-care treatment in end-stage heart failure, as well as greatly expand treatment to previously unreached patients.
Genetika+ is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.
PeekMed is a 3D pre-operative planning system for orthopedic surgery that aims to help the surgeon better treat the patient while reducing costs. With PeekMed the surgeon can plan: - Total Joint Replacements; - Osteotomies; - Fracture reductions; - Virtually any orthopedic procedure. The output of PeekMed system can later be used as an input for: - Navigation systems; - 3D printers; - Robotics; - Mobile devices. PeekMed was founded by Jaime Campos, Sara Silva, and João Pedro Ribeiro in 2015 and is located in Braga, Portugal.
Surgify Medical Oy, founded in 2015 and based in Espoo, Finland, specializes in developing innovative surgical technology aimed at enhancing safety during bone surgeries. The company's flagship product is a neurological burr designed to prevent injuries to nerves and blood vessels, which can occur with traditional surgical drills. This technology is compatible with existing surgical equipment, eliminating the need for additional training for medical personnel. Surgify's solutions have applications in orthopedics and dentistry and are being commercialized in collaboration with Aalto University, with financial support from Tekes, the Finnish Funding Agency for Innovation. The company has also established a partnership with the Neurosurgical Department of Helsinki University Central Hospital to facilitate ongoing communication with clinicians, ensuring that its technology effectively meets the needs of healthcare providers and improves patient outcomes by reducing complications such as bleeding and infections.
New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.
Venari Medical Limited, founded in 2018 and based in Galway, Ireland, develops innovative medical devices aimed at treating chronic venous diseases (CVD). The company's flagship product, BioVena, employs the body's natural healing processes to provide a more effective and less invasive treatment option for conditions such as varicose veins and venous ulcers. Venari Medical seeks to address the significant gap in treatment, as only a small fraction of the 120 million individuals suffering from venous disease in the US and EU receive adequate care. Their technology not only offers a safer alternative to existing methods but also targets the underserved population of venous ulcer patients who currently rely on ineffective compression bandaging. By widening the indications for superficial venous ablation, Venari Medical aims to reduce the annual costs associated with venous ulcers, which total approximately $33 billion for insurers in these regions. The company's commitment to patient-centered solutions positions it to disrupt traditional treatment practices that have seen limited innovation in recent years.
Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.
Filterlex Medical Ltd. is a medical device startup based in Yokneam, Israel, focused on developing innovative solutions in the cardiovascular field. Established in 2015, the company is dedicated to creating advanced embolic protection devices aimed at minimizing the risk of stroke and other complications during catheter-based structural heart procedures. Their flagship device, CAPTIS, is designed for intuitive deployment and retrieval, providing full-body embolic protection by effectively deflecting, capturing, and removing embolic particles. The development of Filterlex's technology is rooted in a comprehensive understanding of existing products' limitations, addressing unmet needs within the medical community. The company is currently seeking seed funding to further advance its mission.
Syntach develops a cardiac support device to improve the care of the rapidly-growing number of people with heart failure.
Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Vivasure Medical Limited is a medical device company based in Galway, Ireland, focused on the research, development, and manufacturing of arterial and venous closure devices utilizing its proprietary PerQseal technology. The company specializes in creating polymer implants and delivery systems aimed at facilitating minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, specifically designed to close large arteriotomies during transcatheter procedures like transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical aims to enhance patient outcomes in vascular access procedures through innovative medical solutions.
NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, particularly focusing on conditions like chronic obstructive pulmonary disease (COPD) and asthma. The company has created a nanosensor-based wearable device that detects subtle changes in a patient's respiratory condition, allowing for early identification and intervention at home. This proactive approach aims to improve patient outcomes by enabling healthcare professionals to address respiratory deteriorations before they reach critical stages, thereby reducing the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation is committed to enhancing the management of chronic respiratory conditions through innovative technology.
HumanITcare is a digital health company delivering a telemedicine platform for monitoring remotely real-life data of chronic patients using Artificial Intelligence. HumanITcare is improving clinical outcomes and reducing clinical costs by providing an accurate remote patient monitoring system.
PROSION is a pharmaceutical & drug discovery start-up company.
The ZygoFix is a medical device company.
Microsure B.V., founded in 2016 and based in Son, Netherlands, specializes in the development of advanced robotic systems for microsurgery. The company's flagship product, MUSA, is designed to assist surgeons in performing intricate procedures, including lymphatic surgery, free flap surgery, and hand surgery. The Microsure motion stabilizer system enhances surgical precision and control, addressing the physical limitations faced by microsurgeons. This technology aims to improve the quality of microsurgical procedures, thus expanding treatment options for patients. The system has demonstrated its efficacy in clinical trials, successfully facilitating microsurgical operations for lymphedema at Maastricht UMC+. Microsure is focused on accelerating the market introduction and sales of its innovative surgical systems.
ADVITOS GmbH is a medical technology company based in Munich, Germany, specializing in extracorporeal multiple organ support therapy products for hospitals. Founded in 2004, the company offers the ADVanced organ support treatment, which utilizes a unique method known as ADVOS to facilitate blood purification. This innovative approach allows for the simultaneous removal of water-soluble and protein-bound toxins from the liver, lungs, and kidneys, while also correcting metabolic and respiratory acidosis. The ADVOS system operates using standard dialysis accesses and flow rates, eliminating the need for gas exchangers for CO2 removal. This technology aims to enhance the treatment outcomes for patients suffering from liver and kidney failure.
Gasgon Medical is a medical device company focused on enhancing the safety and efficiency of intravenous (IV) infusions. By developing innovative products, the company addresses the challenges faced by medical staff in administering IV medications, aiming to reduce potential harm to patients. Gasgon Medical's devices are designed to minimize the risk of Vascular Air Embolism, thereby improving overall patient outcomes and supporting clinicians in delivering high-quality healthcare.
Smart4Diagnostics GmbH is a Munich-based company founded in 2018 that specializes in the production of digital data fingerprints for human blood samples. The company has developed a device designed for precise blood sample measurement, aiming to enhance the accuracy and reliability of diagnostic processes. By focusing on innovative solutions in the medical technology sector, Smart4Diagnostics contributes to advancements in healthcare diagnostics.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
NEOS Surgery S.L. is a Barcelona-based company specializing in the research, design, development, and commercialization of implantable medical devices for neurosurgery. Founded in 2003, NEOS focuses on innovative solutions for cranial and spinal surgical applications, including its proprietary BHID cranial fixation system, which is designed for placement in the burr hole of a craniotomy. The company is committed to meeting the needs of neurosurgeons and patients, ensuring its products are both effective and compliant with stringent quality standards, including ISO certifications. By capturing market demands, NEOS aims to create high-value medical devices that enhance surgical outcomes and contribute to advancements in the neurosurgery field.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
Developer of non-invasive inhalers designed for the treatment of respiratory disorders. The company's device generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, creating multiple momentary dilating forces that gently pry open the collapsed airways, enabling doctors to treat chronic obstructive pulmonary disease by smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
Developer of non-invasive inhalers designed for the treatment of respiratory disorders. The company's device generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, creating multiple momentary dilating forces that gently pry open the collapsed airways, enabling doctors to treat chronic obstructive pulmonary disease by smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
CarThera SAS specializes in the design and development of therapeutic ultrasound-based medical devices aimed at treating brain disorders. Founded in 2010 and headquartered in Paris, France, the company has developed innovative devices such as SonoProbe, which addresses conditions like brain tumors, epilepsy, metastases, and meningioma. Another key product is SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier, enhancing the delivery and concentration of therapeutic molecules for the treatment of primary brain tumors. Through these advancements, CarThera is focused on improving treatment outcomes for patients with serious neurological conditions.
CarThera SAS specializes in the design and development of therapeutic ultrasound-based medical devices aimed at treating brain disorders. Founded in 2010 and headquartered in Paris, France, the company has developed innovative devices such as SonoProbe, which addresses conditions like brain tumors, epilepsy, metastases, and meningioma. Another key product is SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier, enhancing the delivery and concentration of therapeutic molecules for the treatment of primary brain tumors. Through these advancements, CarThera is focused on improving treatment outcomes for patients with serious neurological conditions.
Resistell is a antibiotic resistance test.
At Quantib we come to work every day to help physicians solve the hardest challenges they face when diagnosing patients. Our smart software analyzes medical images to unravel secrets hidden to the naked eye. Are you excited to learn more about how artificial intelligence techniques can move healthcare forward and help our marketing department tell this story to the world? We’d love for you to join our tight team of 22 conquering the medical world with deep learning software.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Ventinova Medical, founded in 2013, focuses on the development and marketing of innovative medical devices for airway management and patient ventilation. The company specializes in creating single-use ventilation devices designed to control both inspiration and expiration during artificial airflow, actively assisting in the removal of gases from the lungs. This unique approach enhances patient recovery, particularly in critical situations where blood flow and oxygen saturation are compromised. Ventinova aims to revolutionize traditional ventilation practices by leveraging advanced technology and extensive medical expertise to deliver solutions that exceed current standards in the medical field.
Ventinova Medical, founded in 2013, focuses on the development and marketing of innovative medical devices for airway management and patient ventilation. The company specializes in creating single-use ventilation devices designed to control both inspiration and expiration during artificial airflow, actively assisting in the removal of gases from the lungs. This unique approach enhances patient recovery, particularly in critical situations where blood flow and oxygen saturation are compromised. Ventinova aims to revolutionize traditional ventilation practices by leveraging advanced technology and extensive medical expertise to deliver solutions that exceed current standards in the medical field.
Operator of an online medical platform intended to help doctors by making informed decisions around clinical diagnosis. The company's platform catalogs clinical information from peer-reviewed medical literature and utilizes artificial intelligence diagnostic engines to extract relevant insights, enabling doctors to map clinical knowledge for fast and informed clinical decision-making.
SOMAprobes S.L. develops healthcare technology for magnetic resonance imaging detection of bacterial pathogens at the onset of infectious disease. The company was incorporated in 2014 and is based in Donostia, Spain.
ADVITOS GmbH is a medical technology company based in Munich, Germany, specializing in extracorporeal multiple organ support therapy products for hospitals. Founded in 2004, the company offers the ADVanced organ support treatment, which utilizes a unique method known as ADVOS to facilitate blood purification. This innovative approach allows for the simultaneous removal of water-soluble and protein-bound toxins from the liver, lungs, and kidneys, while also correcting metabolic and respiratory acidosis. The ADVOS system operates using standard dialysis accesses and flow rates, eliminating the need for gas exchangers for CO2 removal. This technology aims to enhance the treatment outcomes for patients suffering from liver and kidney failure.
Revolutionary electromagnetic endoscopy accessory to automatize polyp detection
Revolutionary electromagnetic endoscopy accessory to automatize polyp detection
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
Developer of a medical platform intended to deliver clinical decision support for remote care of heart patients with pacemakers. The company's platform leverages machine learning and ethnography to monitor cardiac devices remotely and uses advanced analytics to predict health conditions, enabling chronic patients with digital healthcare that monitors implanted cardiac devices.
EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware and software components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Rockfield Medical Devices is an innovative SME in the area of human centered design process in the medical device industry. The company is led by its founder and has a very strong team made up of several acknowledged experts from the medical device industry and from research and design. Rockfield aims to be a leading innovator in the enteral feeding market globally and strives to achieve exemplary end user satisfaction with their plug and play technologies through innovative design, usability and mobility.
Plasmacure, located in Eindhoven, the Netherlands, focuses on developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. This innovative approach not only targets and eliminates bacteria but also promotes cell proliferation and enhances microcirculation. By addressing these critical factors, Plasmacure's technology helps healthcare professionals reduce the risk of amputation and improve the overall quality of life for patients suffering from chronic wounds.
Rockfield Medical Devices is an innovative SME in the area of human centered design process in the medical device industry. The company is led by its founder and has a very strong team made up of several acknowledged experts from the medical device industry and from research and design. Rockfield aims to be a leading innovator in the enteral feeding market globally and strives to achieve exemplary end user satisfaction with their plug and play technologies through innovative design, usability and mobility.
FEops is a recognized pioneer in the field of physics-based simulations for minimally invasive cardiovascular devices and procedures. They apply this technology from bench to bed, by offering advice to medical device companies as well as to medical specialists and physicians.
Their computer simulations have proven to provide medical device developers and manufacturers with unique insights, thereby speeding up R&D processes and supporting device safety. Physicians, for their part, benefit from new patient-specific insights that help them work more efficiently while, most importantly, improving patient safety.
MeMed Diagnostics Ltd. is a personalized diagnostics company established in 2009 and based in Tirat Carmel, Israel. The firm specializes in developing diagnostic solutions that focus on distinguishing between bacterial and viral infections to enhance patient care and reduce healthcare costs. Its flagship product, MeMed BV, is a test that analyzes patients' immune responses to differentiate between infection types. Additionally, the ImmunoDx platform combines proprietary biomarkers and algorithms to provide rapid and actionable insights for healthcare professionals, thereby addressing the challenge of antibiotic misuse, which is prevalent in healthcare systems worldwide. By accurately identifying the source of infection, MeMed's diagnostics aim to prevent inappropriate antibiotic prescriptions, mitigate the emergence of resistant bacterial strains, and ultimately improve treatment outcomes for infectious diseases.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
FEops is a recognized pioneer in the field of physics-based simulations for minimally invasive cardiovascular devices and procedures. They apply this technology from bench to bed, by offering advice to medical device companies as well as to medical specialists and physicians.
Their computer simulations have proven to provide medical device developers and manufacturers with unique insights, thereby speeding up R&D processes and supporting device safety. Physicians, for their part, benefit from new patient-specific insights that help them work more efficiently while, most importantly, improving patient safety.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics designed to improve skin health. The company focuses on the skin microbiome, a complex ecosystem of beneficial and harmful bacteria that plays a crucial role in skin conditions such as acne, eczema, rosacea, and aging. S-Biomedic employs advanced modulation-based technology to selectively harness beneficial bacteria, creating products that promote the rebalancing of the skin microbiome. By utilizing the latest advancements in microbiology and dermatology, their offerings aim to restore healthy skin and address various dermatological concerns. Through this innovative approach, S-Biomedic provides therapeutic solutions in both the dermatology and cosmetic sectors, enhancing the overall health and beauty of the skin.
NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, particularly focusing on conditions like chronic obstructive pulmonary disease (COPD) and asthma. The company has created a nanosensor-based wearable device that detects subtle changes in a patient's respiratory condition, allowing for early identification and intervention at home. This proactive approach aims to improve patient outcomes by enabling healthcare professionals to address respiratory deteriorations before they reach critical stages, thereby reducing the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation is committed to enhancing the management of chronic respiratory conditions through innovative technology.
MindPeak GmbH is a Hamburg-based company founded in 2018 that specializes in developing software tools for visual diagnosis using artificial intelligence and deep learning. Its primary focus is on assisting pathologists in achieving reproducible cancer diagnostics. One of its key products, BreastAI, quantifies breast cancer immunohistochemistry (IHC) and can be integrated as a service within third-party software applications. MindPeak also optimizes workflows in pathological analysis, demonstrating its commitment to enhancing efficiency in the field. The company maintains a strategic partnership with Gestalt Diagnostics, further expanding its collaborative efforts in advancing diagnostic technologies.
Bluedrop Medical Limited, founded in 2014 and based in Galway, Ireland, develops and commercializes an Internet of Things-enabled device that facilitates early detection of diabetic foot ulcers. The device conducts daily scans of patients' feet and transmits the data to the cloud for analysis using advanced algorithms. This technology is designed to identify skin abnormalities early, thereby reducing the risk of amputation, a serious complication faced by many diabetics due to peripheral neuropathy. With an estimated 25% of diabetics likely to develop foot ulcers, the company's innovation addresses a critical healthcare need and aims to improve patient outcomes while potentially lowering healthcare costs associated with diabetes-related amputations.
Imaqen Ltd. is a Finnish healthcare technology company developing a new pre-screening solution for early detection of cancer. The innovation offers a non-invasive patient examination and it is suitable for use in wide range of healthcare facilities. The utilised method is protected by patents. Their team consists of experienced diagnostic imaging and clinical research professionals with solid track records in successful product development and global sales and marketing.
Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.